CKD-MBD: Comfort in the trough of the U

Nephrology Dialysis Transplantation

Volumn 26, Issue 6, 2011, Pages 1764-1766

  Cunningham, John ^a   Silver, Justin ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; C REACTIVE PROTEIN; CINACALCET; FERRITIN; PARATHYROID HORMONE; PHOSPHOROUS ACID;

BONE DENSITY; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIALYSIS; EDITORIAL; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

BONE DISEASES, METABOLIC; CALCIUM; HUMANS; KIDNEY FAILURE, CHRONIC; MINERALS; PARATHYROID HORMONE; PHOSPHORUS; RENAL DIALYSIS; SURVIVAL RATE;

EID: 79958167515     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr205     Document Type: Editorial

References (8)

1. National Kidney FoundationK/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (Suppl): S1-S201.
2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work GroupKDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; 113: S1-130.
3. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218. (Pubitemid 39031360)
4. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530.
5. Qureshi AR, Alvestrand A, Divino-Filho JC et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 2002; 13 (Suppl 1): S28-S36.
6. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780. (Pubitemid 44215354)
7. Chertow GM, Pupim LB, Block GA et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2007; 2: 898-905.
8. Gutiérrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592